Drugs / TIV2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07431853 Comparator | Feb 2026 → Jun 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07431853 ↗ |
| Modality | Vaccine | “Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.” NCT07431853 ↗ |
| Route | Intramuscular | “Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.” NCT07431853 ↗ |